In September, several domestic companies focused on the field of cell and gene therapy (CGT) announced progress in financing. This article will share basic information about its 7 companies based on publicly available materials.

1. Xingsairui has successfully completed tens of millions of yuan in angel round financing

On September 14th, Hangzhou Xingsai Ruizhen Biotechnology Co., Ltd. (hereinafter referred to as "Xingsai Ruizhen") announced the completion of tens of millions of yuan in angel round financing and officially launched the angel+round financing plan! This round of financing is jointly invested by Fosun Pharma's Rehabilitation Capital New Drug Innovation Fund and Chuangrui Investment Jiaxing Chuangyan Fund. This round of financing will be used for the continuous promotion of core pipelines and platforms, as well as the construction of the company's team and research and development laboratories.

Xingsai Ruizhen was founded in July 2022 and incubated by the New Drug Innovation Fund of Rehabilitation Capital. It is a platform based company focused on cell therapy and regenerative medicine transformation. The company has been committed to continuously innovating through regenerative medicine technology and developing excellent iPSC organ transplant replacement products, bringing revolutionary treatment options to patients waiting for organ transplantation. The unique layout of the regenerative medicine pipeline, efficient research team, leading technology platform, and rapidly advancing multiple key research and development projects have gained recognition and favor from numerous investors. Among them, the CRG-101 pipeline is a globally leading iPSC derived corneal endothelial cell product, which will soon advance to the clinical application stage; The pancreatic islet cell pipeline derived from CRG-002 iPSC has also made significant progress. The company has also established three iPSC regenerative medicine technology platforms, CRG iPSC (somatic cell reprogramming platform), CRG-EDIT (gene editing platform), and CRG-XDIF (stem cell multidirectional differentiation platform).

2. Beise Biotechnology completes A2 round of financing

On September 12th, Beise Biotechnology announced the completion of its A2 round of financing, with a total amount of tens of millions of RMB. This round of financing is led by the AEF Greater Bay Area Entrepreneurship Fund managed by Gobi Partners GBA, and the funds will be used to strengthen Beise Biotechnology's R&D team, optimize product pipeline, accelerate clinical trials, and lay a solid foundation for future commercialization. In addition, the company also plans to establish business bases in the Greater Bay Area, with Hong Kong as the core to support internationalization, continuous research and development innovation, and international cooperation and exchange activities.

Founded in 2021, Best Biotech is a technology driven innovation enterprise focused on fundamental innovation in the field of gene editing. It is a pioneer in global gene editing and cellular gene therapy research and development. Since its establishment, the company has been committed to developing the world's first cell therapies and gene editing products, particularly demonstrating great potential in the treatment of cancer and genetic diseases. Beise Biotechnology has developed a series of core technologies in the field of gene editing, including ePE guided editing, AccuBase ® gene editing system, CasH gene editing technology, BEAT-CART technology, and in vivo targeted delivery technology. Among them, the AccuBase ® gene editing system has the characteristic of global free implementation (FTO), which enables efficient and zero off target gene editing in vitro and in vivo. This system is also the world's first therapy that uses base editing to endow NK cells with targeted specificity. The company has built nearly 2500 square meters of GMP compliant cell production facilities to meet the needs of clinical grade cell therapy research and production. In addition to NK510, the company's product pipeline also includes multiple base edited NK cell products for hematological malignancies and autoimmune diseases, as well as general CAR immunotherapy products and in vivo gene editing.

3. Zhixinhao is announcing the completion of its Pre-A+round of financing

Recently, EndoCell announced the completion of its Pre-A+round of financing, which was jointly invested by Panlin Capital, Leo Capital, and Jintai Jinhong. The funds raised in this round will mainly be used for preclinical research and the implementation of Phase I and II clinical trials.

EndoCell was founded in 2019, led by researcher Cheng Xin from the Center for Excellence and Innovation in Molecular Cell Science of the Chinese Academy of Sciences. The research and development team led by EndoCell has profound technical accumulation and rich research and development experience in the field of in vitro directional differentiation of stem cells and in vitro regeneration of tissues and organs. EndoCell is focusing on the reconstruction of human tissues and organs. The first pipeline is regenerative islets, which is expected to be used for the treatment of diabetes with islet injury characteristics.

4. Beijing Errui Xinyue completes Pre-A+round of financing

Recently, Beijing Errui Xinyue Technology Co., Ltd. (referred to as Errui Xinyue) announced that it has obtained strategic investment, but the investor has not disclosed it. This strategic investment will be used to support the R&D team of Errui Xinyue in expanding their R&D scale, enhancing their technological strength, and further promoting the company's leading position in the medical technology field.

As a medical technology solution provider established on August 16, 2021, Errui Xinyue focuses on the research and application of extracellular vesicle related technologies. This strategic investment will help Errui Xinyue accelerate technological innovation and promote the development of the life and health field. Errui Xinyue's extracellular vesicle technology has broad application prospects in the medical field, including disease diagnosis, treatment, and drug delivery. The company provides efficient and safe solutions for the medical industry through continuous research and optimization of extracellular vesicle technology.

5. Huateng Biotechnology completes Series B financing, with gene edited large animal models as the core, accelerating the new quality development of CRO platform

On September 21st, Guangzhou Huateng Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as "Huateng Biotechnology") announced the successful completion of tens of millions of yuan in Series B financing. This financing has received strong support from Guangzhou Financial Holding Fund and Tianhe Fund, and is also the second well-known institutional financing for Huateng Biotechnology after completing the A+round of financing in 2023. As of now, the company has accumulated nearly 100 million yuan in financing. The funds raised this time will mainly be used to promote the construction of a gene edited large animal model library, enhance preclinical CRO service capabilities, further expand market layout and brand building, accelerate the research and development process of innovative pharmaceutical and medical products, and assist customers in the transformation of scientific research achievements.

Huateng Biotechnology is located in Huangpu District, Guangzhou, and is a national high-tech enterprise specializing in biopharmaceutical research and development outsourcing services (CRO). The core team of the company is led by academicians and gathers a team of senior scientists from top universities, research and development institutions, and enterprises at home and abroad. Based on gene edited large animal models (such as small pigs and rabbits), covering fields such as scientific research services, innovative drugs, and preclinical efficacy and safety evaluation of medical devices. The company now has qualifications for the production of multiple types of large experimental animals, a database of over 200 animal models, and a multi platform R&D service center. It is a large-scale one-stop preclinical R&D service institution in the Guangdong Hong Kong Macao Greater Bay Area.

6. Hegia Biotech completes A2 round of financing

On September 3rd, Hangzhou Hejiya Biopharmaceutical Co., Ltd. announced that it has completed tens of millions of yuan in A2 round financing, led by Huangpu Biopharmaceutical Fund and followed by Nanwan Baiao Fund.

Hejiya Biotechnology is committed to building a delivery technology platform and drug development in the field of siRNA. It has established a complete end-to-end siRNA drug development platform from target discovery to clinical concept validation (POC), and has a professional team with rich experience in the field covering the entire lifecycle from early research and development to industrialization. The company has developed multiple siRNA delivery technology platforms with completely independent intellectual property rights. Among them, the MVIP delivery platform is the world's first dual coupled siRNA delivery technology for liver derived diseases, which has unique stability to prevent siRNA degradation. Its high efficiency, safety, and long-term effectiveness have been verified through multiple pipelines of Hegia Biotech's clinical research and preclinical studies. MVIP is the first siRNA delivery technology platform in China to obtain global patent authorization. The DDP delivery platform is a second-generation siRNA delivery technology developed by the company for liver related diseases. It targets the delivery of siRNA drugs for multiple concurrent diseases in complex disease fields, and can simultaneously deliver two or more siRNAs. Currently, the pipeline has entered the IND Enabling Studies stage. The HJYNSdp delivery platform is an siRNA delivery technology developed by the company for neurological diseases, which can target not only the central nervous system (CNS) but also the peripheral nervous system (PNS). Currently, multiple pipelines are in the preclinical compound confirmation stage.

7. Weike Biotechnology completes Pre-A round of financing

Recently, Shanghai Weike Biotechnology Co., Ltd. completed tens of millions of Pre-A round financing, led by Bangming Capital and followed by Shenzhen High tech Investment. This round of financing will help Weike Biotechnology accelerate the development and upgrading of its cell and gene therapy safety evaluation technology platform, biological breeding and testing technology platform, and overseas business expansion.

Founded in March 2021, Weike Biotech's core members mainly come from Heidelberg University, the German National Cancer Research Center, and GeneWerk. With over 20 years of experience in carrier integration site (ISA) research and safety evaluation, Weike Biotech has participated in non clinical and clinical research on more than 80 gene therapy products worldwide, assisting in the market application of multiple star products, including Glybera, the world's first gene therapy product, Kymriah, and CARVYKTI, China's first FDA approved CAR-T drug, which accounts for over 80% of FDA marketed products. The core technology system of WEGO Biotech, LAM-PCR S-EPTS/LM PCR、TES， It has great potential for application in various fields such as cell and gene therapy safety evaluation and biological breeding.